Lilly Now in Phase 3 Clinical Trial for Covid-19 Drug Baricitinib
New York-listed Eli Lilly and Company announced today that the first patient has been enrolled in a Phase 3 randomized, double-blind, placebo–controlled study to evaluate the efficacy and safety of…